University of Ioannina
Ο ρόλος του μεταμορφωτικού αυξητικού παράγοντα-β (TGF-β) στην πνευμονική υπέρταση
Abstract
dc:descriptionPulmonary arterial hypertension (PAH) is an uncommon but serious disease with high morbidity and mortality. Thus, the need for deeper understanding of the pathophysiological mechanisms is imperative. The present study examined the pathophysiological role of Transforming Growth Factor-β (TGF-β). TGF-β represents a super-family of multifunctional cytokines. Mutations in all TGF-β receptor sub-types result in increased proliferation of smooth muscle cells in the pulmonary arterial wall. The present study examined the role of TGF-β in the rat model of pulmonary hypertension, induced by monocrotaline injection. In the first part of the study, we administered a TGF-β pan-antibody, aiming at inhibition of the progression of early-stage PAH. In the second part, we administered a TGF-β pan-antibody at advanced PAH stages. We compared this approach with endothelin receptor blockade and we examined the effects of combined treatment. Endothelin-1 is the most potent vasoconstrictor hitherto discovered and has a central role in the pathophysiology of pulmonary hypertension. As a result, endothelin-1 receptor blockers represent the mainstay of treatment of PAH.In the first part of the study, we used 20 Wistar rats. One week after PAH induction, a TGF-β pan-antibody was administered intraperitoneally (n=10) for one week, at a dosage of 0,1mg/kg daily, via an osmotic mini-pump. In the remainder 10 animals, no other pharmaceutical intervention was made, whereas 10 additional animals served as normal controls. Two weeks after monocrotaline injection, exercise tolerance was evaluated and right ventricle systolic pressure was measured, followed by histological assessment of heart and lungs.In the second part of the study, we examined 4 groups (B, C, D, E+ F, n=15 rats each), in which PAH was induced as above, whereas 15 additional rats (group A) served as controls. Treatment was commenced 4 weeks after monocrotaline injection. Bosentan (a dual endothelin receptor antagonist) was administered once daily in group B at a dose of 300mg/kg by gavage for 4 weeks. In group C, TGF-β pan-antibody (1D11) was administered intravenously every three days at a dosage of 5mg/kg for 15 days. In group D, combined treatment was administered, namely TGF-β pan-antibody (1D11) and bosentan, as described above. In group F, an indifferent antibody (13C4) was administered intravenously every three days at a dosage of 5mg/kg for 15 days. At the end of treatment, exercise tolerance was evaluated and right ventricle systolic pressure was measured, followed by histological assessment of heart and lungs.We observed attenuation of PAH development after TGF-β receptor pan-anibody administration in both parts of the study. In treated groups, right ventricular systolic pressure was reduced (by 27.8% and 45% respectively), exercise tolerance was increased, right ventricular hypertrophy was decreased (by 26.6% and 30% respectively) and pulmonary vascular remodeling was attenuated. TGF-β inhibition improved hemodynamic and histological parameters. In the second part of the study, no differences were observed between the three treatment groups, namely TGF-β inhibition, endothelin-receptor blockade and combined treatment. TGF-β plays an important pathophysiological role in PAH and its inhibition may emerge as an important therapeutic approach.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Μεγάλου, Αικατερίνη
- Megalou, Aikaterini
Subjects
dc:subject × 9Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/30161